The KDM1A Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte cell line through CRISPR/Cas9-mediated gene disruption of the KDM1A locus. This heterogenous knockout pool provides a powerful loss-of-function model for investigating KDM1A-dependent epigenetic regulation, transcriptional control, and oncogenic signaling in a T-cell context. The polyclonal format captures a broad spectrum of genetic alterations, making it particularly suitable for pooled functional screens, dose-response studies, and analyses of population-level phenotypes in leukemia research.
Jurkat cells are a well-established human T-cell leukemia line originally derived from a patient with acute lymphoblastic leukemia. They retain many features of native T lymphocytes, including robust cytokine production, inducible T-cell receptor signaling, and responsiveness to apoptotic and proliferative cues. As a suspension cell line, Jurkat cells facilitate a wide range of biochemical, molecular, and pharmacological assays and are widely employed in immunological and cancer biology investigations. Their T-cell leukemia origin makes them directly relevant to studies of T-cell acute lymphoblastic leukemia (T-ALL) pathobiology and drug response.
KDM1A (lysine-specific demethylase 1, also known as LSD1) is a flavin-dependent amine oxidase that catalyzes the demethylation of histone H3 lysine 4 (H3K4me1/me2) and, in certain contexts, histone H3 lysine 9 (H3K9me1/me2). Through these activities, KDM1A functions as a key epigenetic regulator that can either repress or activate gene transcription depending on its associated protein partners. KDM1A forms a corepressor complex with RCOR1 (CoREST), HDAC1/2, and BHC80 (PHF21A) to remove activating H3K4me marks, silencing tumor suppressors such as CDKN1A (p21) and CDH1 (E-cadherin). Conversely, when recruited by transcription factors such as the androgen receptor (AR) or estrogen receptor, KDM1A can demethylate repressive H3K9me marks to facilitate gene activation. Its activity is modulated by upstream regulators including SNAI1, TCF7L2, CEBPA, and TLX (NR2E1), and it governs downstream targets like MYC, CCND1, and Vimentin, positioning KDM1A at the nexus of multiple signaling cascades including Wnt/??-catenin, Notch, TGF-??, and p53 pathways.
In the context of T-cell leukemia, KDM1A is frequently overexpressed and contributes to malignant transformation by suppressing differentiation and pro-apoptotic programs while sustaining proliferative gene expression networks. The Jurkat polyclonal knockout model therefore provides a physiologically relevant system to dissect KDM1A??s role in maintaining the T-ALL phenotype. Loss of KDM1A function in these cells is expected to derepress key tumor suppressors, alter histone methylation landscapes, and impair oncogenic signaling, offering insights into epigenetic dependencies in leukemia. This model is especially valuable for validating KDM1A as a therapeutic target and for benchmarking small-molecule LSD1 inhibitors in a human T-ALL background.
These polyclonal knockout cells support a broad array of experimental applications, including epigenetic regulation studies, cancer biology, drug target validation, and T-cell signaling research. Representative assays compatible with this model include western blotting for histone methylation marks (e.g., H3K4me1/me2, H3K9me1/me2), RT-qPCR for KDM1A target genes, ChIP-qPCR to assess locus-specific histone modifications, flow cytometry for apoptosis (Annexin V), MTT or similar proliferation assays, TCF/LEF reporter assays for Wnt activity, and co-immunoprecipitation of KDM1A-interacting complexes. For additional information on product specifications, validation data, or technical support, please contact Ascent Research.
